CodeMap® Compliance Briefing: August 21, 2019
Editor's Welcome: Over the past three years, the AMA has added a number of new codes for multi-organism, nucleic acid based, syndromic test panels to the CPT® for respiratory, gastrointestinal, and central nervous system infectious agents. CMS based Medicare reimbursement for these panels on existing single organism tests at quite high values. New technology is now available in more cost effective configurations from a number of manufacturers, prompting the creation of a number of new codes specifically designed to bring reimbursement in line with that of commercial payers. Today, we will discuss the existing and new codes now available for syndromic panels and explore future Medicare reimbursement and coverage requirements.
Sorry, access to this content requires a current subscription.
Click here for publications catalog.
CPT copyright 2021 American Medical Association. All rights reserved.
* The responsibility for the content of any "National Correct Coding Policy" included in this product is with the Centers for Medicare and Medicaid
Services and no endorsement by the AMA is intended or should be implied. The AMA disclaims responsibility for any consequences or liability attributable to or related
to any use, nonuse, or interpretation of information contained in this product.